Different Levels of Autophagy Activity in Mesenchymal Stem Cells Are Involved in the Progression of Idiopathic Pulmonary Fibrosis

Hongxia Tao, Qin Lv, Jing Zhang, Lijuan Chen, Yang Yang, Wei SunStem 2024 · DOI

TL;DR

This review explores the critical role of autophagy, a cellular recycling process, in the progression of Idiopathic Pulmonary Fibrosis (IPF). It highlights how dysregulated autophagy in Mesenchymal Stem Cells (MSCs) contributes to their aging and loss of therapeutic function, suggesting that modulating autophagy could be a promising strategy for treating IPF.

What Problem Does This Paper Address?

Idiopathic Pulmonary Fibrosis (IPF) is a devastating, age-related lung disease characterized by progressive scarring, with limited effective treatments and a poor prognosis. Mesenchymal Stem Cells (MSCs) show promise for regenerative therapy in IPF due to their repair and immunomodulatory capabilities. However, MSCs themselves age and lose their efficacy, particularly in the context of IPF. This paper addresses the crucial question of why MSCs lose their therapeutic potential in IPF and how this relates to their cellular aging. Specifically, it investigates the role of autophagy, a fundamental cellular process for maintaining homeostasis, in the health and function of MSCs and its implications for IPF progression.

Methods

This paper is a review article, meaning it synthesizes existing research rather than presenting new experimental data. The authors analyze and discuss findings from numerous studies related to:

  • Autophagy mechanisms: The review details the different types of autophagy (microautophagy, chaperone-mediated autophagy, macroautophagy) and the key molecular players involved, such as the mTOR pathway and AMPK.
  • MSC biology: It covers the properties of MSCs, their therapeutic potential, and how their function is influenced by aging and the inflammatory microenvironment.
  • IPF pathogenesis: The paper discusses the cellular and molecular mechanisms underlying IPF, including fibroblast activation, epithelial-mesenchymal transition, and the role of various signaling pathways.
  • Autophagy in disease: It specifically examines how altered autophagy contributes to the aging of MSCs and the progression of IPF, drawing connections between these processes.
  • Therapeutic strategies: The review explores current and potential future treatments for IPF, with a focus on how modulating autophagy in MSCs could enhance their therapeutic efficacy.

Datasets

Not discussed in the paper. This is a review article synthesizing existing literature.

Key Insights and Ideas

  • Autophagy as a double-edged sword: Autophagy is essential for cellular health, clearing damaged components and maintaining homeostasis. However, both insufficient and excessive autophagy can be detrimental. In MSCs, insufficient autophagy leads to senescence and loss of function, while excessive autophagy can promote apoptosis.
  • MSC aging and IPF are linked to autophagy decline: As MSCs age, their autophagic activity naturally declines. This decline is exacerbated in the context of IPF, contributing to their reduced ability to repair lung tissue and their increased susceptibility to inflammatory damage.
  • Targeting autophagy for IPF therapy: Modulating autophagy in MSCs presents a promising therapeutic avenue. Enhancing autophagy could potentially rejuvenate aged MSCs, restore their regenerative capacity, and improve their effectiveness in treating IPF.
  • Context-specific autophagy modulation is key: The paper emphasizes that the precise level and type of autophagy modulation needed will likely depend on the specific cell type and the stage of the disease, suggesting a need for nuanced therapeutic approaches.
  • Current IPF drugs and autophagy: Existing IPF drugs like pirfenidone and nintedanib have been shown to influence autophagy, hinting at the broader importance of this pathway in IPF treatment.

Key Results

Not applicable, as this is a review article. The "results" are the synthesis of findings from numerous studies, which are presented as key insights and ideas.

Limitations and Future Work

  • Complexity of autophagy regulation: The paper acknowledges that the precise mechanisms by which autophagy influences MSC function and IPF progression are complex and not fully understood. The dual role of autophagy (pro-survival vs. pro-death) depending on the context requires further investigation.
  • Need for further research: The authors stress the need for more research to fully elucidate the role of autophagy in different cell types involved in IPF (e.g., fibroblasts, alveolar macrophages) and to develop specific, context-dependent strategies for targeting autophagy in MSC-based therapies.
  • Clinical translation: While promising, translating these findings into effective clinical treatments for IPF requires further validation through preclinical and clinical studies. The development of novel MSC therapies that specifically target the autophagy signaling pathway is highlighted as a future direction.

Summary updated

Abstract

Idiopathic pulmonary fibrosis (IPF) is an age-related lung interstitial disease that occurs predominantly in people over 65 years of age and for which there is a lack of effective therapeutic agents. It has demonstrated that mesenchymal stem cells (MSCs) including alveolar epithelial cells (AECs) can perform repair functions. However, MSCs lose their repair functions due to their distinctive aging characteristics, eventually leading to the progression of IPF. Recent breakthroughs have revealed that the degree of autophagic activity influences the renewal and aging of MSCs and determines the prognosis of IPF. Autophagy is a lysosome-dependent pathway that mediates the degradation and recycling of intracellular material and is an efficient way to renew the nonnuclear (cytoplasmic) part of eukaryotic cells, which is essential for maintaining cellular homeostasis and is a potential target for regulating MSCs function. Therefore, this review focuses on the changes in autophagic activity of MSCs, clarifies the relationship between autophagy and health status of MSCs and the effect of autophagic activity on MSCs senescence and IPF, providing a theoretical basis for promoting the clinical application of MSCs.
BibTeX
@inproceedings{tao2024different,
  author = {Hongxia Tao and Qin Lv and Jing Zhang and Lijuan Chen and Yang Yang and Wei Sun},
  title = {{Different Levels of Autophagy Activity in Mesenchymal Stem Cells Are Involved in the Progression of Idiopathic Pulmonary Fibrosis}},
  booktitle = {Stem},
  year = {2024},
  doi = {10.1155/2024/3429565},
}
Figure